The role of galectin-3 and its genetic variants in tumor risk and survival of patients with surgically resected early-stage non-small cell lung cancer.
Enzyme-linked immunosorbent assay
galectin-3
gene expression
non-small cell lung cancer
single nucleotide polymorphism genotyping
Journal
Turk gogus kalp damar cerrahisi dergisi
ISSN: 1301-5680
Titre abrégé: Turk Gogus Kalp Damar Cerrahisi Derg
Pays: Turkey
ID NLM: 100887967
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
21
05
2020
accepted:
16
09
2020
entrez:
9
6
2021
pubmed:
10
6
2021
medline:
10
6
2021
Statut:
epublish
Résumé
The aim of this study was to investigate the possible relationship between galectin-3 gene variants, serum level, gene expression level, and the risks and survivals of resectable non-small cell lung cancer patients. The rs4644 and rs4652 variants of galectin-3 were genotyped by TaqMan single nucleotide polymorphism assay using genomic deoxyribonucleic acid isolated from the peripheral blood of 65 (54 males, 11 females; mean age: 60.1±11.9 years; range, 34 to 83 years) with Stage IA-IIIA non-small cell lung cancer who underwent primary surgical treatment and 95 healthy individuals (48 males, 47 females; mean age: 53.9±13.5 years; range, 32 to 87 years) between March 2017 and September 2018. Circulating galectin-3 levels in serum samples of the patient and control groups were assessed by enzyme-linked immunosorbent assay. Messenger ribonucleic acid expression of galectin-3 in tumor and surrounding tissues of the patient group was examined by real-time quantitative polymerase chain reaction. Both predictive and prognostic significance of the results were analyzed. The presence of angiolymphatic invasion was significant in the patients with rs4652 AA genotype (p=0.04). Serum galectin-3 levels were significantly higher in the patients than the controls (p<0.0001). The patients with rs4644 CA/CC (p<0.0001 and p<0.0001) and rs4652 AA/AC (p=0.001 and p<0.0001) genotypes had higher serum galectin-3 levels than their corresponding controls. Serum galectin-3 levels increased in the presence of vascular invasion in patients with both rs4644 AC (p=0.03) and rs4652 AC (p=0.019) genotypes. The receiver operating characteristic curve suggested serum galectin-3 level as a strong predictive marker for the patient group with a cut-off value of 17.089 ng/mL (area under the curve: 0.910±0.04; 95% confidence interval: 0.832-0.988; p<0.001). Univariate analysis revealed the association of lower serum galectin-3 levels with better survival (p=0.048). Multivariate survival analysis showed that only high serum galectin-3 levels tended to be related to survival of the patients (hazard ratio: 5.106; 95% confidence interval: 0.956-27.267; p=0.056). The presence of galectin-3 gene variants may lead to histopathological differences among patients with non-small cell lung cancer. Serum galectin-3 level may be a valuable diagnostic biomarker and be associated with survival of these patients.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to investigate the possible relationship between galectin-3 gene variants, serum level, gene expression level, and the risks and survivals of resectable non-small cell lung cancer patients.
METHODS
METHODS
The rs4644 and rs4652 variants of galectin-3 were genotyped by TaqMan single nucleotide polymorphism assay using genomic deoxyribonucleic acid isolated from the peripheral blood of 65 (54 males, 11 females; mean age: 60.1±11.9 years; range, 34 to 83 years) with Stage IA-IIIA non-small cell lung cancer who underwent primary surgical treatment and 95 healthy individuals (48 males, 47 females; mean age: 53.9±13.5 years; range, 32 to 87 years) between March 2017 and September 2018. Circulating galectin-3 levels in serum samples of the patient and control groups were assessed by enzyme-linked immunosorbent assay. Messenger ribonucleic acid expression of galectin-3 in tumor and surrounding tissues of the patient group was examined by real-time quantitative polymerase chain reaction. Both predictive and prognostic significance of the results were analyzed.
RESULTS
RESULTS
The presence of angiolymphatic invasion was significant in the patients with rs4652 AA genotype (p=0.04). Serum galectin-3 levels were significantly higher in the patients than the controls (p<0.0001). The patients with rs4644 CA/CC (p<0.0001 and p<0.0001) and rs4652 AA/AC (p=0.001 and p<0.0001) genotypes had higher serum galectin-3 levels than their corresponding controls. Serum galectin-3 levels increased in the presence of vascular invasion in patients with both rs4644 AC (p=0.03) and rs4652 AC (p=0.019) genotypes. The receiver operating characteristic curve suggested serum galectin-3 level as a strong predictive marker for the patient group with a cut-off value of 17.089 ng/mL (area under the curve: 0.910±0.04; 95% confidence interval: 0.832-0.988; p<0.001). Univariate analysis revealed the association of lower serum galectin-3 levels with better survival (p=0.048). Multivariate survival analysis showed that only high serum galectin-3 levels tended to be related to survival of the patients (hazard ratio: 5.106; 95% confidence interval: 0.956-27.267; p=0.056).
CONCLUSION
CONCLUSIONS
The presence of galectin-3 gene variants may lead to histopathological differences among patients with non-small cell lung cancer. Serum galectin-3 level may be a valuable diagnostic biomarker and be associated with survival of these patients.
Identifiants
pubmed: 34104515
doi: 10.5606/tgkdc.dergisi.2021.20141
pmc: PMC8167472
doi:
Types de publication
Journal Article
Langues
eng
Pagination
212-222Informations de copyright
Copyright © 2021, Turkish Society of Cardiovascular Surgery.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Références
Oncol Lett. 2017 Dec;14(6):8144-8149
pubmed: 29250191
J Natl Cancer Inst. 2003 Mar 19;95(6):470-8
pubmed: 12644540
Neurosci Lett. 2012 Jun 14;518(1):1-4
pubmed: 22465244
Nucleic Acids Res. 1988 Feb 11;16(3):1215
pubmed: 3344216
Acta Paediatr. 2007 May;96(5):644-7
pubmed: 17376185
Cell Oncol (Dordr). 2012 Jun;35(3):175-80
pubmed: 22476961
Oncogene. 2015 Jan 15;34(3):290-302
pubmed: 24441045
Oncotarget. 2015 Mar 10;6(7):4936-52
pubmed: 25669973
Gen Thorac Cardiovasc Surg. 2019 Aug;67(8):704-711
pubmed: 30903521
Chest. 2009 Jul;136(1):260-271
pubmed: 19584208
J Thorac Oncol. 2007 Aug;2(8):694-705
pubmed: 17762335
Oral Oncol. 2008 Jan;44(1):86-93
pubmed: 17350328
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
Spectrochim Acta A Mol Biomol Spectrosc. 2014 Jan 24;118:572-7
pubmed: 24091345
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Glycoconj J. 2004;19(7-9):543-9
pubmed: 14758078
J Exp Med. 2010 Aug 30;207(9):1981-93
pubmed: 20713592
Lung Cancer. 2011 Jan;71(1):3-10
pubmed: 20951465
Oncology. 2018;95(3):156-162
pubmed: 29847825
Arch Biochem Biophys. 1998 Jan 1;349(1):7-20
pubmed: 9439577
Acta Oncol. 2011 Aug;50(6):745-56
pubmed: 21767170
Urol Oncol. 2013 Jan;31(1):74-81
pubmed: 21396839
Cancer Res. 2008 Dec 15;68(24):10045-50
pubmed: 19074869
Clin Rheumatol. 2011 Sep;30(9):1227-33
pubmed: 21475983
Oncol Res Treat. 2017;40(9):533-539
pubmed: 28848207
Nat Rev Cancer. 2005 Jan;5(1):29-41
pubmed: 15630413
Eur J Biochem. 1999 Sep;264(2):569-76
pubmed: 10491105